Stock Detail
ARQULE INC
Drug Manufacturers Other
ARQL @ Yahoo Finance | ARQL Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $5.70 | $5.95 | $-0.21 | -3.55% | 0.00 | $5.91 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $5.83 | $5.68 | 166,310 | 306.5M | 317,172 | -13.90 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 6.05 | 5.88 | 5.78 | 5.61 | 5.51 |
Stock Profile
ArQule, Inc., a biotechnology company, engages in the research and development of small-molecule cancer therapeutics based on its Activated Checkpoint Therapy (ACT) platform. The ACT platform is designed to produce small molecule compounds that selectively kill cancer cells while leaving normal cells unharmed. Its primary product consists of ARQ 501, a Phase I oncology product for cancer patients with solid tumors. The company also has products in preclinical and research stages. ArQule was founded in 1993 and is headquartered in Woburn, Massachusetts.